ALGOTX
14.3.2023 08:02:19 CET | Business Wire | Press release
European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M€ in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
Bervin Bouani, Investment Director at Turenne Capital, commented: “We are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with Stéphane and his outstanding team to transform AlgoTx into a global pain player.”
Following the demonstration of ATX01’s early clinical safety and low systemic passage in Phase 1, the Phase 2 “ACT” study will now assess ATX01’s ability to reduce pain in adult CIPN patients – a program granted “fast-track” designation by FDA. In parallel, the Phase 2 “EASE” study will explore ATX01’s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted “Orphan Disease Designation” in the US and Europe.
Stéphane Thiroloix, Founder & CEO of AlgoTx, says: “It is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.”
Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.
« We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions », says Pauline de Breteuil Senior Partner UI Investissement / FCPI Majycc Innovation Santé.
About AlgoTx
AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at www.algotx.com
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 / Study in Erythromelalgia.
ABOUT TURENNE GROUP/RELYENS INNOVATION SANTÉ
Launched in 2014, Relyens Innovation Santé is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Santé (Health Division of Turenne Group), Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.
Turenne Group, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company’s innovation, development and transfer projects. As an independent player, the Group has assets of €1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches.
For more information: www.relyens.eu/fr / www.turennecapital.com
About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
For more information, please visit: www.bpifrance.com – Follow us on Twitter : @bpifrance - @BpifrancePresse
About Omnes
Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than €5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com
About UI Investissement
UI Investissement is an independent, specialized company in the development of unlisted French companies with €1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Santé fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow's health. The roots of Majycc Innovation Santé are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Volante Technologies launches “Vol360i” Agentic AI at the core of payments, setting a new global standard for intelligence in banking9.6.2026 15:00:00 CEST | Press release
Agents deliver configurable, confidence-based automation and predictability to financial institutions through exception handling, routing, and SLA monitoring Volante Technologies, the global leader in Payments as a Service (PaaS), today announced that its Payments Platform and PaaS operations are now powered by its “Vol360i” Agentic AI. The core upgrade unlocks autonomous and semi-autonomous collaboration to reduce manual intervention, significantly increasing straight-through processing (STP) rates to over 95%, accelerating exception resolution, and proactively managing SLA performance. Vol360i is immediately available to Volante banking and financial institution clients, with four main operating principles guiding Volante’s agentic framework to deliver a frictionless payments experience: Prevent Agents: Eliminate failures before they occur, boosting reliability and reducing customer-impacting errors. Repair Agents: Self-healing AI fixes problems in real time, allowing operators to fo
Boomi Adds Snowflake Cortex Agents Support to Agentstudio to Enable Unified AI Agent Governance9.6.2026 15:00:00 CEST | Press release
Snowflake Cortex Agents support in Boomi Agentstudioenables joint customers to govern all their agents in a single, vendor-agnostic control tower Boomi, the data activation company for AI and an Elite Snowflake partner, today announced the launch of Snowflake Cortex Agents support for Agentstudio. This new integration, powered by Snowflake, enables organizations to monitor, manage, and govern every Cortex Agent that is part of their agentic workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609131798/en/ Boomi Adds Snowflake Cortex Agents Support to Agentstudio to Enable Unified AI Agent Governance "Customers are scaling AI agents into production, and partners are bringing new solutions to market at record speed, both powered by Boomi Agentstudio,” said Steve Lucas, Chairman and CEO at Boomi. “This dual momentum reflects the unique strength of the Boomi Enterprise Platform, empowering innovation while ensuring gove
Xsolla Brings Direct-to-Consumer Commerce Expertise to Gamesforum Hamburg 2026 With Keynote and Panel Appearances9.6.2026 14:01:00 CEST | Press release
As An Exclusive Global Partner Of The Gamesforum Series, Xsolla Takes Two Stages In Hamburg, Headlined By A Keynote With AppsFlyer On Web Shop Attribution Xsolla, a global leader in video game commerce, today announced its participation in Gamesforum Hamburg 2026, taking place June 9–10, 2026, at NORD EVENT Panoramadeck in Hamburg, Germany. As an Exclusive Global Partner of the Gamesforum series, Xsolla will bring its direct-to-consumer commerce expertise to one of Europe's leading gatherings for mobile game growth and monetization, with Jane Startseva, Vice President of Business Development, EMEA, taking the stage across two sessions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609166526/en/ Graphic: Xsolla Xsolla's presence in Hamburg underscores its role at the center of gaming's shift toward direct-to-consumer commerce: On June 9 at 10:00 AM, Jane joined Adam Smart, Global Director of Product – Gaming at AppsFlyer,
Duetti Expands Funding Offerings for Independent Artists With Two New Programs9.6.2026 14:01:00 CEST | Press release
Master Tracks as Young as Six Months Now Eligible for Acquisition Deals; New Remix Program Expands Collaboration Opportunities Duetti Inc. (“Duetti” or the “Company”), the music company that partners with independent artists and songwriters to buy, manage, and market their catalogs, announces today a significant expansion of its funding offering. Artists can now sell their master recording tracks, or parts thereof, in as little as six months after release - substantially earlier than the company’s prior two-year threshold. Duetti is also launching its new Remix Program, which allows independent artists to create remixes, covers, and other derivative works from Duetti’s 30,000-track catalog (across both masters and compositions). In return, artists can receive upfront cash compensation, ongoing royalty % share, 0% distribution fees, and dedicated marketing support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609063445/e
Clearlake Completes Strategic Acquisition of Pathway Capital Management9.6.2026 14:00:00 CEST | Press release
Expands Clearlake’s private markets solutions for institutional and private wealth marketsCombined platform represents over $185 billion in assets under management with more than 500 global employees Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced the completion of its acquisition of Pathway Capital Management (“Pathway”), a global provider of private market solutions for institutional and wealth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609839186/en/ The strategic acquisition significantly expands Clearlake’s private markets platform, adding complementary capabilities and reinforcing its position as a leading diversified alternative asset manager. Founded in 1991, Pathway manages more than $95 billion in assets and brings a proven track record ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom